Investigational Drug Details
| Drug ID: | D213 |
| Drug Name: | Luseogliflozin |
| Synonyms: | Luseogliflozin |
| Type: | Chemical drug |
| DrugBank ID: | DB12214 |
| DrugBank Description: | Luseogliflozin has been used in trials studying the treatment of Diabetes Melltius, Type 2. |
| PubChem ID: | 11988953 |
| CasNo: | 898537-18-3 |
| Repositioning for NAFLD: | No |
| SMILES: | O(C)c1c(cc(c(c1)C)Cc1ccc(cc1)OCC)[C@@H]1S[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O |
| Structure: |
|
| InChiKey: | WHSOLWOTCHFFBK-ZQGJOIPISA-N |
| Molecular Weight: | 434.554 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 0 on-going (JPRN-jRCTs031190238) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0433 | JPRN-jRCTs031190238 | Not applicable | Recruiting | No Results Available | 03/03/2020 | 18 October 2021 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A04506 | 33594581 | Diabetes Ther | Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial. | Details |
| A08737 | 32006266 | Adv Exp Med Biol | Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. | Details |
| A10550 | 31292843 | Clin J Gastroenterol | Long-term luseogliflozin therapy improves histological activity of non-alcoholic steatohepatitis accompanied by type 2 diabetes mellitus. | Details |
| A13284 | 30051943 | Hepatol Res | Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial). | Details |
| A15768 | 28719078 | Diabetes Obes Metab | Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. | Details |
| A19388 | 26594248 | Diabetol Metab Syndr | Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. | Details |
| A50654 | 35312970 | Diabetes Ther | Additional Effect of Luseogliflozin on Semaglutide in Nonalcoholic Steatohepatitis Complicated by Type 2 Diabetes Mellitus: An Open-Label, Randomized, Parallel-Group Study. | Details |